英国皮肤科医生对成人中重度特应性湿疹治疗方案的全国性调查
该研究通过在线调查英国顾问级皮肤科医生,了解成人顽固性中重度特应性湿疹的治疗选择、决策因素及证据缺口。结果显示光疗(尤其是窄谱中波紫外线)是最常用的首选方案(46%),硫唑嘌呤是最常用的首选系统药物。受访者认为未来试验应优先研究甲氨蝶呤。
要点
- 光疗(常为窄谱UVB)是46%受访者首选的一线治疗。
- 36%的皮肤科医生首选系统治疗,硫唑嘌呤为最常用一线药物。
- 甲氨蝶呤是最常用的二线治疗,且被视为未来试验优先方向。
核心结论
- 光疗尤其是窄谱中波紫外线是受访者治疗成人顽固性中重度特应性湿疹的首选一线方案。
- 硫唑嘌呤被广泛用作长期维持治疗。
研究设计与样本
- 研究为针对英国顾问级皮肤科医生的在线调查。
主要发现
- 46%的受访者首选光疗或补骨脂素-长波紫外线(通常为窄谱中波紫外线)。
- 36%的皮肤科医生首选系统治疗,最常用一线药物依次为硫唑嘌呤、口服糖皮质激素、环孢素和甲氨蝶呤。
- 甲氨蝶呤是最常见的二线治疗。
关键数值与推荐
- 影响光疗和系统药物决策的关键因素包括受访者的临床经验、基线检查结果(系统药物)以及对疗效和急慢性副作用特征的了解。
- 最重要的证据缺口包括治疗的相对有效性、现有方案的替代选择以及长期维持治疗的安全性。
- 受访者建议未来试验应优先研究甲氨蝶呤。
临床怎么用
- 英国皮肤科医生倾向将光疗(尤其是窄谱中波紫外线)作为成人顽固性中重度特应性湿疹的一线选择。
- 硫唑嘌呤常用于长期维持治疗,甲氨蝶呤多作为二线选择。
局限性
- 调查研究设计存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about U.K. dermatologists' treatment approaches towards adult patients with recalcitrant moderate-to-severe atopic eczema. OBJECTIVES: We wanted to learn about (i) treatment approaches used for this disease in the U.K.; (ii) factors that influence treatment decisions and (iii) perceived gaps in evidence on treatment safety and efficacy, and priorities for future trials. METHODS: We conducted an online survey of consultant-level dermatologists in the U.K. RESULTS: Sixty-one respondents from over 30 centres reported on management of moderate-to-severe atopic eczema in adults, outwith the context of an acute flare. Phototherapy or psoralen-ultraviolet A was the most common therapeutic modality chosen first line (46%), and this was usually narrowband ultraviolet B. Systemic therapy was chosen as a first-line approach by 36% of dermatologists. Azathioprine was the commonest drug reported being used as first line followed by oral corticosteroids, ciclosporin and methotrexate. Methotrexate was the most common second-line treatment of respondents. The key factors that influenced decision making on the use of phototherapy and systemic agents were the respondent's clinical experience, results of baseline tests (systemic agents) and knowledge of both efficacy and acute and chronic side-effect profiles. The most important evidence gaps identified were the relative effectiveness of treatments, the alternatives to current approaches and the safety of long-term maintenance treatment. With regard to future trials, respondents suggested that priority should be given to studies involving methotrexate. CONCLUSIONS: While survey study designs have limitations, we found that phototherapy, in particular narrowband ultraviolet B, was respondents' preferred first-line treatment for adults with recalcitrant moderate-to-severe atopic eczema, perhaps reflecting access to, and clinical experience of, this approach. Azathioprine is widely used as a longer-term maintenance treatment.
引用
- Taylor K, Swan DJ, Affleck A, et al. Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol. 2017. PMID: 27943248. doi:10.1111/bjd.15235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。